IRAK4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL112548	0.49	13/20
SCHEMBL87061	0.56	11/20
Penthiopyrad (SCHEMBL18701)	0.39	9/20
Lefradafiban (SCHEMBL50399)	0.33	8/20
SCHEMBL113391	0.47	7/20
SCHEMBL72955	0.44	6/20
SCHEMBL111358	0.34	6/20
SCHEMBL84781	0.42	5/20
SCHEMBL111464	0.35	5/20
Linifanib (SCHEMBL93804)	1.00	4/20
SCHEMBL12688	0.46	4/20
SCHEMBL112162	0.42	4/20
SCHEMBL112638	0.42	4/20
SCHEMBL112547	0.42	4/20
SCHEMBL111924	0.37	4/20
SCHEMBL144118	0.61	3/20
SCHEMBL143818	0.61	3/20
SCHEMBL143827	0.59	3/20
SCHEMBL144183	0.58	3/20
SCHEMBL143148	0.56	3/20

Clinical trials — most relevant to IRAK4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	PHASE4	NOT_YET_RECRUITING
Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis	PHASE4	NOT_YET_RECRUITING
Efficacy & Safety of Resatorvid in Adults With Severe Sepsis	PHASE3	COMPLETED
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Azithromycin Plus Hydroxychloroquine for COVID-19 Infection	PHASE3	WITHDRAWN
Reducing Abundance of Human Papilloma Virus in Women by Taking Probiotic	PHASE2/PHASE3	WITHDRAWN
Efficacy of Vitamin D on the Clinical Management of Pediatric Patients With Asthma	PHASE3	UNKNOWN
IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.	PHASE2	UNKNOWN
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms	PHASE1/PHASE2	RECRUITING
Cilostazol in Parkinson's Disease	PHASE2	NOT_YET_RECRUITING
Leniolisib for Immune Dysregulation in PIDs	PHASE2	ACTIVE_NOT_RECRUITING
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia	PHASE1	NOT_YET_RECRUITING
The Effects of GLA on Human Volunteers	PHASE1	COMPLETED
Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined	EARLY_PHASE1	RECRUITING
RNA Cloning and Visualization in Human Atherosclerosis	nan	COMPLETED
MicroRNAs and Cytokines in Peri-Implantitis Tissue	nan	UNKNOWN
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry Bad Cholesterol in the Blood	nan	COMPLETED
Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis	nan	COMPLETED
Deep Phenotyping of Cutaneous Lupus Erythematosus	nan	UNKNOWN
Diagnosis of Inflammatory Bowel Disease	nan	NOT_YET_RECRUITING
The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear	nan	UNKNOWN
Probiotics and Systemic Inflammation in Patients With Metabolic Syndrome and High Cardiovascular Risk	nan	WITHDRAWN
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases	nan	UNKNOWN
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population	nan	RECRUITING
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers	nan	COMPLETED
Activation of a Cutaneous Inflammasome in the Skin of Hidradenitis Suppurativa Patients	nan	COMPLETED
Expression of Toll-like Receptors 3 , 7 and 9 in Peripheral Blood Mononuclear Cells of COVID-19 Patients	nan	UNKNOWN
Inflammation Regulation in Obese Patients	nan	COMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a IRAK4 binder may also engage these)

Protein	Name	Similarity
Q1RMT8	—	0.995	Q1RMT8 →
Q8R4K2	—	0.994	Q8R4K2 →
P52332	—	0.989	P52332 →
Q78EA7	—	0.988	Q78EA7 →
Q90344	—	0.987	Q90344 →
Q8AXC7	—	0.987	Q8AXC7 →
Q76II0	—	0.987	Q76II0 →
Q28317	—	0.986	Q28317 →
Q54RB7	—	0.986	Q54RB7 →
Q28889	—	0.986	Q28889 →
Q7JQ32	—	0.986	Q7JQ32 →
G5ECP4	—	0.986	G5ECP4 →
Q54Y55	—	0.986	Q54Y55 →
Q9QVP9	—	0.986	Q9QVP9 →
Q2HWD6	—	0.986	Q2HWD6 →
Q91909	—	0.986	Q91909 →
P34892	—	0.986	P34892 →
Q09435	—	0.986	Q09435 →
Q05652	—	0.986	Q05652 →
Q9TZC4	—	0.985	Q9TZC4 →
Q23681	—	0.985	Q23681 →
P79750	—	0.985	P79750 →
Q03145	—	0.985	Q03145 →
Q5D892	—	0.985	Q5D892 →
Q09488	—	0.985	Q09488 →
O16544	—	0.985	O16544 →
Q9SIB6	—	0.985	Q9SIB6 →
A8WPG9	—	0.985	A8WPG9 →
P32865	—	0.985	P32865 →
BTK	Tyrosine-protein kinase BTK	0.985	landscape →